In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models

Autores
Ruiz, María Carolina; Resasco, Agustina; Di Virgilio, Ana Laura; Ayala, Miguel Ángel; Cavaco, Isabel; Cabrera, Silvia; Alemán, José; León, Ignacio Esteban
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1nu without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.
Facultad de Ciencias Exactas
Centro de Química Inorgánica
Facultad de Ciencias Veterinarias
Materia
Química
Veterinaria
Platinum
Osteosarcoma
Spheroids
Apoptosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/131150

id SEDICI_2e92187e6f7c470c66bfe30b522d4b43
oai_identifier_str oai:sedici.unlp.edu.ar:10915/131150
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma modelsRuiz, María CarolinaResasco, AgustinaDi Virgilio, Ana LauraAyala, Miguel ÁngelCavaco, IsabelCabrera, SilviaAlemán, JoséLeón, Ignacio EstebanQuímicaVeterinariaPlatinumOsteosarcomaSpheroidsApoptosisPlatinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.Facultad de Ciencias ExactasCentro de Química InorgánicaFacultad de Ciencias Veterinarias2019-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf681-692http://sedici.unlp.edu.ar/handle/10915/131150enginfo:eu-repo/semantics/altIdentifier/issn/1432-0843info:eu-repo/semantics/altIdentifier/issn/0344-5704info:eu-repo/semantics/altIdentifier/doi/10.1007/s00280-019-03773-xinfo:eu-repo/semantics/altIdentifier/pmid/30661096info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:23:33Zoai:sedici.unlp.edu.ar:10915/131150Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:23:34.121SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
title In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
spellingShingle In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
Ruiz, María Carolina
Química
Veterinaria
Platinum
Osteosarcoma
Spheroids
Apoptosis
title_short In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
title_full In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
title_fullStr In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
title_full_unstemmed In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
title_sort In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
dc.creator.none.fl_str_mv Ruiz, María Carolina
Resasco, Agustina
Di Virgilio, Ana Laura
Ayala, Miguel Ángel
Cavaco, Isabel
Cabrera, Silvia
Alemán, José
León, Ignacio Esteban
author Ruiz, María Carolina
author_facet Ruiz, María Carolina
Resasco, Agustina
Di Virgilio, Ana Laura
Ayala, Miguel Ángel
Cavaco, Isabel
Cabrera, Silvia
Alemán, José
León, Ignacio Esteban
author_role author
author2 Resasco, Agustina
Di Virgilio, Ana Laura
Ayala, Miguel Ángel
Cavaco, Isabel
Cabrera, Silvia
Alemán, José
León, Ignacio Esteban
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Química
Veterinaria
Platinum
Osteosarcoma
Spheroids
Apoptosis
topic Química
Veterinaria
Platinum
Osteosarcoma
Spheroids
Apoptosis
dc.description.none.fl_txt_mv Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.
Facultad de Ciencias Exactas
Centro de Química Inorgánica
Facultad de Ciencias Veterinarias
description Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.
publishDate 2019
dc.date.none.fl_str_mv 2019-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/131150
url http://sedici.unlp.edu.ar/handle/10915/131150
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1432-0843
info:eu-repo/semantics/altIdentifier/issn/0344-5704
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00280-019-03773-x
info:eu-repo/semantics/altIdentifier/pmid/30661096
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
681-692
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846064290524561408
score 13.22299